Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, leading to loss of muscle control and eventually paralysis.
SOD1 ALS: AMT-162 Gene Therapy
We are testing a new gene therapy for adults with SOD1 amyotrophic lateral sclerosis to see if it is safe and well-tolerated. We’re also exploring its potential effects on the disease.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you willing and able to provide informed consent for this study?
- Do you have any serious health conditions that might put you at risk if you participate in a study?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Adeno-associated Viral Vector
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Umea University
Neurology
Karlstad, Sweden
Sponsor: uniQure biopharma B.V.
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.